Scribe Therapeutics, Inc.
- SCTX · Nasdaq
- Biological Products, (No Diagnostic Substances)
- Alameda, CA
- CIK 0001853921
Updated from SEC filings through
Top things to know
Executives
- Benjamin L. Oakes President, CEO Form 4, July 27, 2026
- David Parrot Chief Financial Officer Form 4, July 27, 2026
- Svetlana Lucas Chief Business Officer Form 4, July 27, 2026
Scribe Therapeutics, Inc. is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in Alameda, CA. It trades as SCTX on Nasdaq. Benjamin L. Oakes is President, CEO.
Five-year financials
We have no annual financials for this company yet.
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Benjamin L. Oakes CEO I Scribe Therapeutics | President, CEO | Form 4, July 27, 2026 |
| David Parrot CFO Scribe Therapeutics | Chief Financial Officer | Form 4, July 27, 2026 |
| Svetlana Lucas | Chief Business Officer | Form 4, July 27, 2026 |
What Scribe Therapeutics, Inc. does
We’re unlocking the future of medicine with CRISPR-based therapeutics that are safe and effective enough to transform everyone's lifetime risk for disease.
Company website description, 10-K for the year ending November 7, 2026
Shares and governance
| Shares outstanding | 18.9 million (as of November 6, 2026) | 10-Q, November 12, 2026 |
|---|
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| July 28, 2026 | Ventures LLC Avoro Director | Buy | 2,391,238 | $36.3M | Form 4, July 28, 2026 |
| July 28, 2026 | Behzad Aghazadeh Director | Buy | 2,391,238 | $36.3M | Form 4, July 28, 2026 |
| July 28, 2026 | Capital Advisors LLC Avoro Director | Buy | 2,391,238 | $36.3M | Form 4, July 28, 2026 |
| July 27, 2026 | Carl L. Gordon Director | Buy | 1,000,000 | $15.0M | Form 4, July 29, 2026 |
| July 27, 2026 | Capital GP VIII LLC OrbiMed Director | Buy | 1,000,000 | $15.0M | Form 4, July 29, 2026 |
| July 27, 2026 | Advisors Llc Orbimed Director | Buy | 1,000,000 | $15.0M | Form 4, July 29, 2026 |
| July 23, 2026 | David Parrot Chief Financial Officer | Buy | 2,666 | $40K | Form 4, July 27, 2026 |
| July 23, 2026 | Svetlana Lucas Chief Business Officer | Buy | 3,000 | $45K | Form 4, July 27, 2026 |
Recent 8-K events
- 8-K filed 2026-11-12
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-09-02
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-27
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
Frequently asked questions about Scribe Therapeutics, Inc.
- What does Scribe Therapeutics, Inc. do?
- In its own words, from Item 1 of its 10-K: "We’re unlocking the future of medicine with CRISPR-based therapeutics that are safe and effective enough to transform everyone's lifetime risk for disease."
- Who is the CEO of Scribe Therapeutics, Inc.?
- Benjamin L. Oakes, President, CEO, as named in a 4 filed July 27, 2026.
- Who is the CFO of Scribe Therapeutics, Inc.?
- David Parrot, Chief Financial Officer, as named in a 4 filed July 27, 2026.
- Where is Scribe Therapeutics, Inc. headquartered?
- Alameda, CA.
- What is Scribe Therapeutics, Inc.'s stock ticker?
- SCTX on Nasdaq.
- What industry is Scribe Therapeutics, Inc. in?
- Biological Products, (No Diagnostic Substances), SIC code 2836.
- What is Scribe Therapeutics, Inc.'s website?
- scribetx.com. Investor relations: https://investors.scribetx.com/.
- When does Scribe Therapeutics, Inc. report earnings next?
- December 2, 2026. Source: pg_future_events.
- Is Scribe Therapeutics, Inc. a public company?
- Yes. Scribe Therapeutics, Inc. files with the SEC under CIK 0001853921 and trades as SCTX.
- How many shares of Scribe Therapeutics, Inc. are outstanding?
- 18.9 million shares as of November 6, 2026, from its 10-Q filed November 12, 2026.
- Have Scribe Therapeutics, Inc. insiders traded stock recently?
- Since July 23, 2026, officers and directors reported 0 open-market sales and 8 purchases worth about $154M on Forms 4 and 5. The most recent: Ventures LLC Avoro (Director) bought 2,391,238 shares on July 28, 2026.